Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT) Abstract #1391

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.
Aim(s): We assessed the efficacy and toxicity of YTate sequenced with LuTate induction in this setting.
Materials and methods: 26 patients (pts) (17 male; 27-74 y.o) completed PRRT using 1-2 YTate cycles sequenced with 2-3 LuTate cycles (median cumulative activity YTate 6.5GBq, LuTate 21GBq) were reviewed. All had at least one lesion >4cm transaxial diameter. 58% had ENETS Grade 2/3, and 73% FDG-avid disease. 7 pts were treated for uncontrolled symptoms, 19 for progressive disease.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Grace Kong
Keywords: PRRT, Y-90

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)
Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Grace Kong
Keywords: PRRT
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT